Á¾¾ç±«»çÀÎÀÚ ¾ïÁ¦Á¦ ºÒÀÀ °Á÷¼º ôÃß¿° ȯÀÚ¿¡¼ ¹ß»ýÇÑ ¾Æ¹Ð·ÎÀ̵åÁõ
A Case of Secondary Amyloidosis in a Patient with Ankylosing Spondylitis Refractory to TNF-¥á Inhibitor
´ëÇѳ»°úÇÐȸÁö 2014³â 87±Ç 4È£ p.514 ~ p.519
À̹ÎÁø(Lee Min-Jin) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
À̽±Ù(Lee Seong-Geun) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹ÚÀº°æ(Park Eun-Kyoung) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
Àå¼±¹Ì(Jang Sun-Mi) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¹é¼º¹Î(Baek Sung-Min) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
¼Û±Ù¾Ï(Song Geun-Am) - ºÎ»ê´ëÇб³ ÀÇÇÐÀü¹®´ëÇпø ³»°úÇб³½Ç
±è±ÙÅÂ(Kim Geun-Tae) - °í½Å´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
Abstract
Secondary amyloidosis occurs in patients with chronic inflammatory diseases, such as rheumatoid arthritis (RA) and ankylosing spondylitis (AS). The major therapeutic approach to secondary amyloidosis involves controlling the underlying inflammatory disease. Tumor necrosis factor-alpha (TNF-¥á) inhibitors have revolutionized the treatment of rheumatic diseases; in many cases dramatic clinical improvement of secondary amyloidosis due to AS has been observed in response to treatment with these agents. However, the development of secondary amyloidosis associated with AS refractory to treatment with TNF-¥á inhibitors has been infrequently reported. Here, we described a case of a 37-year-old male patient with longstanding AS who was diagnosed with secondary amyloidosis due to high disease activity despite treatment with etanercept, adalimumab and infliximab.
Å°¿öµå
Spondylitis, Ankylosing, Amyloidosis, Tumor necrosis factor-alpha
KMID :
0882420140870040514
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)